Exclusive: Japan's Astellas looks to sell dermatology assets - sources
NEW YORK (Reuters) - Japanese drugmaker Astellas Pharma Inc (4503.T) is looking to sell its dermatology portfolio, which could be worth between $500 million and $1 billion, according to three people familiar with the situation.
Astellas has hired London-based investment banking boutique DC Advisory to sell the assets, according to two of the people, who wished to remain anonymous because they are not permitted to speak to the press.
The company's dermatology portfolio, which includes a drug to treat eczema called Protopic, sells products around the world.
The drugmaker, which has $23 billion in market capitalization, is discussing breaking up the business and selling the pieces to different parties to generate a greater premium, said one of the people.
It is unclear how much each of the businesses would fetch.
Breaking up the portfolio and selling it to different parties makes sense particularly because the U.S. patent for Protopic is set to expire next year, opening it up to generic competition, said another of the three persons.
Astellas declined to comment. DC Advisory did not return calls requesting a comment.
(Editing by Maureen Bavdek and Matthew Lewis)
NUSA DUA, Indonesia - The World Trade Organization reached its first ever trade reform deal on Saturday to the roar of approval from nearly 160 ministers who had gathered on the Indonesian island of Bali to decide on the make-or-break agreement that could add $1 trillion to the global economy
SAN FRANCISCO - At Pinterest, the four-year-old online bulletin board service that is valued near $3.8 billion, some 70 percent of the users are female. But the company's board of directors is 100 percent male. | Video
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.